Search - tctmd.com

Displaying 1 - 20 of 73

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Conference News TCT 2017

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

Todd Neale

November 09, 2017

News Conference News TCT 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

Todd Neale

November 08, 2017

Presentation TCT 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presenter: Pamela S. Douglas

November 01, 2017

Presentation TCT 2017

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

Presenter: Steven R. Bailey, Patrick W. Serruys, Angelo Biviano, MD

November 01, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Presentation TCT 2017

TCT 51: Impact of Anticoagulation Therapy on Valve Hemodynamics and Clinical Outcomes After Bioprosthetic Aortic Valve Replacement: A Pooled Analysis of the PARTNER2 Trials

Presenter: Peter C. Block, Lars Sondergaard, Tarun Chakravarty, MD

October 31, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

Shelley Wood

October 31, 2017

Presentation TCT 2017

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Presenter: John G. Webb

October 30, 2017

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

News Opinion Off Script TCT 2017

Off Script: Welcome to TCT 2017 in the Mile High City

Kwan S. Lee

October 29, 2017

Presentation TCT 2017

Take-home Messages and Closing Comments

Presenter: Amal Kumar Banerjee, Rabin dra Nath Chakraborty

October 29, 2017

Presentation TCT 2017

Clinical Case #4: A Complex and High-Risk PCI

Presenter: Anibal A. Damonte, Alejandro O. Palacios, Alejandro Cherro

October 29, 2017

Presentation TCT 2017

Resting Pd/Pa vs FFR for Predicting Coronary Events

Presenter: Gary S. Mintz, Seung-Jung Park, Jung-Min Ahn

October 29, 2017

Presentation TCT 2017

STEMI and Cardiogenic Shock With Comorbidities

Presenter: Ayman Abou El Magd, Mohamed Ahmed Sobhy, Mohamed Loutfi

October 29, 2017

Presentation TCT 2017

Case Presentation 6: BTK Intervention

Presenter: Sergey A. Abugov, Juan F. Granada, Zaza Kavteladze

October 29, 2017

Presentation TCT 2017

Debate: iFR as the Gold Standard Index!

Presenter: Gary S. Mintz, Seung-Jung Park, Justin E. Davies

October 29, 2017

Presentation TCT 2017

Case Presentation #2: Complication Made Simple - Managing Longitudinal Stent Distortion

Presenter: Amal Kumar Banerjee, Rabin dra Nath Chakraborty, Saujatya Chakraborty

October 29, 2017

Advertisement

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

TCT 51: Impact of Anticoagulation Therapy on Valve Hemodynamics and Clinical Outcomes After Bioprosthetic Aortic Valve Replacement: A Pooled Analysis of the PARTNER2 Trials

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Live From Denver: TCT 2017, Day Two

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

The PARTNER 3 Low-risk Trial

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Off Script: Welcome to TCT 2017 in the Mile High City

Take-home Messages and Closing Comments

Clinical Case #4: A Complex and High-Risk PCI

Resting Pd/Pa vs FFR for Predicting Coronary Events

STEMI and Cardiogenic Shock With Comorbidities

Case Presentation 6: BTK Intervention

Debate: iFR as the Gold Standard Index!

Case Presentation #2: Complication Made Simple - Managing Longitudinal Stent Distortion

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content